Clinical trial
Fluoxetine in Pediatric Body Dysmorphic Disorder
NCT00245635 · Montefiore Medical Center, Other · Completed
Key facts
| NCT number | NCT00245635 |
|---|---|
| Title | Fluoxetine in Pediatric Body Dysmorphic Disorder |
| Official title | Fluoxetine in Pediatric Body Dysmorphic Disorder |
| Acronym | FDA BDD |
| Lead sponsor | Montefiore Medical Center, Other |
| Collaborators | Food and Drug Administration (FDA) U.S. Fed |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Body Dysmorphic Disorder |
| Intervention type | Drug |
| Interventions | Fluoxetine, Placebo |
| Enrollment | 43 |
| Start date | Nov 1, 2004 |
| Primary completion | Apr 1, 2012 |
| Completion | Apr 1, 2012 |
| First posted | Oct 28, 2005 |
| Last update posted | Apr 27, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: